AU2001248355A1 - The use of anticoagulant agents in the extracorporeal treatment of blood - Google Patents

The use of anticoagulant agents in the extracorporeal treatment of blood

Info

Publication number
AU2001248355A1
AU2001248355A1 AU2001248355A AU4835501A AU2001248355A1 AU 2001248355 A1 AU2001248355 A1 AU 2001248355A1 AU 2001248355 A AU2001248355 A AU 2001248355A AU 4835501 A AU4835501 A AU 4835501A AU 2001248355 A1 AU2001248355 A1 AU 2001248355A1
Authority
AU
Australia
Prior art keywords
blood
extracorporeal treatment
anticoagulant agents
anticoagulant
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248355A
Inventor
Florian Abel
Peter Bacher
Hans-Ulrich Esslinger
Christopher Parow
Rudi Scherhag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of AU2001248355A1 publication Critical patent/AU2001248355A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001248355A 2000-03-20 2001-03-20 The use of anticoagulant agents in the extracorporeal treatment of blood Abandoned AU2001248355A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19010300P 2000-03-20 2000-03-20
EP00105867 2000-03-20
US60190103 2000-03-20
EP00105867 2000-03-20
PCT/EP2001/003181 WO2001070273A1 (en) 2000-03-20 2001-03-20 The use of anticoagulant agents in the extracorporeal treatment of blood

Publications (1)

Publication Number Publication Date
AU2001248355A1 true AU2001248355A1 (en) 2001-10-03

Family

ID=26070693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001248355A Abandoned AU2001248355A1 (en) 2000-03-20 2001-03-20 The use of anticoagulant agents in the extracorporeal treatment of blood

Country Status (6)

Country Link
EP (1) EP1265639A1 (en)
JP (2) JP5367202B2 (en)
AR (1) AR027686A1 (en)
AU (1) AU2001248355A1 (en)
CA (1) CA2404115A1 (en)
WO (1) WO2001070273A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077426B2 (en) 2012-12-06 2018-09-18 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158564B1 (en) * 1984-03-27 1992-07-15 Transgene S.A. Expression vectors for hirudin, transformed cells and process for the preparation of hirudin
WO1990006128A1 (en) * 1988-12-05 1990-06-14 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
WO1991008229A1 (en) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Hirudine polyalkylene glycol conjugates
JPH05168705A (en) * 1991-06-11 1993-07-02 Toray Ind Inc System removing von willebrand factor
JPH05220218A (en) * 1992-02-13 1993-08-31 Norio Nakabayashi Anti-thrombogenic regeneration cellulose film and manufacture thereof
DE4242655A1 (en) * 1992-12-17 1994-06-23 Behringwerke Ag Use of thrombin inhibitors to inhibit ocular fibrin formation
DE19715504C2 (en) * 1997-04-14 2000-10-26 Max Planck Gesellschaft PMMA membranes with polyethylene glycol-coupled active substances
JP3601662B2 (en) * 1998-07-24 2004-12-15 東洋紡績株式会社 Blood purification membrane with improved antithrombotic properties

Also Published As

Publication number Publication date
EP1265639A1 (en) 2002-12-18
JP2012006964A (en) 2012-01-12
JP2003527442A (en) 2003-09-16
WO2001070273A1 (en) 2001-09-27
AR027686A1 (en) 2003-04-09
JP5367202B2 (en) 2013-12-11
CA2404115A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU775126C (en) Substituted oxazolidinones and their use in the field of blood coagulation
AU2001257620A1 (en) Supplemental heart pump methods and systems for supplementing blood through the heart
AU2002220577A1 (en) Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2002341876A1 (en) Methods and devices for treating diseased blood vessels
AU2002232104A1 (en) Syringe for use in blood analysis
EP1361909A4 (en) Blood collection systems and methods that derive estimated effects upon the donor's blood volume and hematocrit
AU2001289640A1 (en) Intracardiac blood pump
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
PT1757606E (en) Xanthinderivatives for use as medical agents and the preparation thereof
AU2001281369A1 (en) Cardiac disease treatment and device
AU2002347458A1 (en) Device for intracorporeal and extracorporeal purification
AU2001249389A1 (en) Modified blood clotting factors and methods of use
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
AU2002355230A1 (en) Blood dialyzer
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2001274908A1 (en) Use of citrate-containing dialysate for renal dialysis treatment
AU2001232053A1 (en) System for the extracorporeal treatment of blood
AU2001251489A1 (en) Assembly for extracorporeal blood handling and method of use
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2001246754A1 (en) Central venous line catheter and method of preparing the same for the use
AU2001248355A1 (en) The use of anticoagulant agents in the extracorporeal treatment of blood
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders